Results of a phase 1, single-center, open-label study to assess the safety and evaluate the activity of rituximab for the treatment of pemphigus vulgaris

被引：0
|
作者：
Zeichner, Joshua
Blum, Robin
Lebwohl, Mark
Cohen, Steven
机构：
[1] Mt Sinai Med Ctr, New York, NY 10029 USA
[2] Albert Einstein Coll Med, New York, NY USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2007年 / 56卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：AB116 / AB116
页数：1
相关论文
共 50 条
  • [21] Aripiprazole in Children and Adolescents with Conduct Disorder: A Single-Center, Open-Label Study
    Ercan, E. S.
    Uysal, T.
    Ercan, E.
    Ardic, U. A.
    PHARMACOPSYCHIATRY, 2012, 45 (01) : 13 - 19
  • [22] Risperidone in children and adolescents with conduct disorder:: A single-center, open-label study
    Ercan, ES
    Kutlu, A
    Çikoglu, S
    Veznedaroglu, B
    Erermis, S
    Varan, A
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2003, 64 (01): : 55 - 64
  • [23] Pharmacokinetics, Safety, and Tolerability of Tenapanor in Healthy Chinese and Caucasian Volunteers: A Randomized, Open-Label, Single-Center, Placebo-Controlled Phase 1 Study
    Yuan, Gang
    Chen, Yili
    Li, Li
    Wang, Xin
    Wei, Gang
    Zeng, Jiawei
    Hui, Ai-Min
    Jiang, Yueyun
    Zhao, Han
    Diao, Lei
    Zhou, Yongchun
    Xiao, Yinglian
    Chen, Minhu
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2024, 2024
  • [24] An open-label, single-center study to investigate the outcome of treatment on acne scarring using the eMatrix system
    Gold, Michael
    Foster, Amy
    Biron, Julie
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 66 (04) : AB214 - AB214
  • [25] Pharmacokinetics, safety, and tolerability of sodium phenylacetate and sodium benzoate in healthy Japanese volunteers: A phase I, single-center, open-label study
    Endo, Fumio
    Nakamura, Kimitoshi
    Sano, Yuuhei
    Dote, Nobuhito
    Shimizu, Kohei
    Koumura, Emiko
    DRUG METABOLISM AND PHARMACOKINETICS, 2023, 48
  • [26] Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial
    Fowler, Nathan H.
    Davis, R. Eric
    Rawal, Seema
    Nastoupil, Loretta
    Hagemeister, Fredrick B.
    McLaughlin, Peter
    Kwak, Larry W.
    Romaguera, Jorge E.
    Fanale, Michelle A.
    Fayad, Luis E.
    Westin, Jason R.
    Shah, Jatin
    Orlowski, Robert Z.
    Wang, Michael
    Turturro, Francesco
    Oki, Yasuhiro
    Claret, Linda C.
    Feng, Lei
    Baladandayuthapani, Veerabhadran
    Muzzafar, Tariq
    Tsai, Kenneth Y.
    Samaniego, Felipe
    Neelapu, Sattva S.
    LANCET ONCOLOGY, 2014, 15 (12): : 1311 - 1318
  • [27] A single-center prospective pilot open-label study to assess the efficacy of topical application of an oxygen-enriched oil for the treatment of angular cheilitis
    Arduino, Paolo G.
    Cabras, Marco
    Macciotta, Alessandra
    Longhi, Francesca
    Gambino, Alessio
    Broccoletti, Roberto
    JOURNAL OF ORAL SCIENCE, 2022, 64 (01) : 105 - 108
  • [28] Open-label, single-center, safety dose escalation trial of alefacept for the treatment of moderate to severe chronic plaque psoriasis
    Moul, Danielle K.
    Routhouska, Shannon B.
    Korman, Neil J.
    JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2007, 11 (04) : 132 - 136
  • [29] Intrathecal treatment trial of rituximab in progressive MS An open-label phase 1b study
    Bergman, Joakim
    Burman, Joachim
    Gilthorpe, Jonathan D.
    Zetterberg, Henrik
    Jiltsova, Elena
    Bergenheim, Tommy
    Svenningsson, Anders
    NEUROLOGY, 2018, 91 (20) : E1893 - E1901
  • [30] Evaluation of vinpocetine as a therapy in patients with sensorineural hearing loss: A phase II, open-label, single-center study
    Gutierrez-Farfan, Ileana
    Reyes-Legorreta, Celia
    Solis-Olguin, Mauricio
    Alatorre-Miguel, Efren
    Verduzco-Mendoza, Antonio
    Durand-Rivera, Alfredo
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2021, 145 (04) : 313 - 318
12345